$USAC

USA Compression (NYSE: USAC) shows pro forma impact of $912M J-W Power deal

USA Compression Partners (NYSE: USAC) filed an amended report detailing the pro forma impact of its $912 million J-W Power acquisition, which closed in January 2026. The acquisition, valued at approximately $911.6 million (half cash, half equity), is expected to increase net income attributable to common unitholders to $127.2 million for 2025 on a pro forma basis, with basic earnings per unit rising to $0.92. The report includes J-W Energy's audited 2025 financial statements and outlines how purchase accounting adjustments, such as increased property, equipment, goodwill, and long-term debt, affect USA Compression's financial outlook.

Original reporting
Published Mar 31, 2026, 5:09 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Mar 31, 2026, 5:30 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
USA Compression (NYSE: USAC) shows pro forma impact of $912M J-W Power deal — source image
Decision brief

The 30-second read

$USACBullishMed
01

Why it matters

The $912 million acquisition of J-W Power enhances USAC's revenue streams and asset valuation, likely leading to improved investor confidence and stock performance.

02

Market read

The acquisition signifies a strategic move within the energy transportation sector, with potential ripple effects on related companies and industry sentiment.

03

What to watch

Potential integration challenges and market saturation could temper expected gains; macroeconomic factors such as interest rate changes may influence performance.

Timing: Immediate to short-term (next 1-3 months)

Background

USA Compression Partners (USAC) is a key player in energy transportation infrastructure, with recent strategic acquisitions aimed at expanding its asset base and market share.

Company-level read

Ticker impact

$USACBullishHigh confidence
Context

High relevance due to significant acquisition impact and financial outlook revision.

Expected impact

Moderate upward movement expected in USAC stock price over the next 1-3 months.

Evidence & confidence

The pro forma financial improvements and increased net income suggest a solid growth trajectory, supported by the recent acquisition. The inclusion of audited financial statements adds credibility to the projected benefits.

Market effects

Potential positive sentiment in energy transportation and infrastructure sectors due to consolidation activity.

Limited regional impact; primarily affects USAC and related entities.

Low; specific to USAC and its immediate industry.

Counterpoint

Some analysts may view the increased debt and goodwill on USAC's balance sheet as potential risks, possibly leading to overvaluation.

Key entities

  • USA Compression Partners

    A provider of natural gas compression services and infrastructure.

  • J-W Power

    A provider of energy and power solutions, recently acquired by USAC.

Related articles

$USACMed

USA Compression Partners Q2 Earnings Call Highlights

USA Compression Partners (NYSE:USAC) reported Q2 metrics including 4.95 million total fleet horsepower, 92% utilization, and average revenue per revenue-generating horsepower per month of $22.84. Adjusted gross margin was 63.5% and leverage was 3.72x. The firm reaffirmed 2026 outlook for adjusted EBITDA $770m-$800m and distributable cash flow $480m-$510m, plus capex guidance.

$USACMed

USA Compression Partners, LP (USAC): Results of Operations and Financial Condition

USA Compression Partners, LP (USAC) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 usacq22026ex991.htm EX-99.1 Document Exhibit 99.1 News Release USA Compression Partners, LP 8115 Preston Road, Suite 700 Dallas, Texas 75225 usacompression.com USA Compression Partners Reports Second-Quarter 2026 Results DALLAS, Texas, August 4, 2026 — USA Compression P

$ABUSMed

Could Arbutus Biopharma Corporation (ABUS) Turn its Moderna, Inc. (MRNA) Settlement Into a Lasting Biotech Advantage?

Arbutus Biopharma (ABUS) received about $178 million from Moderna (MRNA) as its share of a $950 million noncontingent LNP patent settlement, with reimbursement of legal costs and an expected Q3 dividend tied to Genevant. ABUS reported Q1 2026 revenue of $179.1 million and net income of $169.7 million. Moderna reported Q2 2026 revenue of $145 million and a net loss of $782 million, plus FDA approval for mFLUSIVA.

$IONQMedAI 8/10

Pentagon may see one of quantum computing’s first practical winners

IonQ (IONQ) said DARPA awarded a $28 million contract modification under its It’s About Time program to support production development and 25 Evergreen-05 optical atomic clocks, with a $30 million option for 100 additional clocks. IonQ plans to invest $15 million to scale manufacturing. The company cites timing performance for GPS-denied defense uses.

$CCEYFMedAI 8/10

CanCambria Energy Provides Updated Contingent Resource Evaluation for Flagship Deep Gas Project, Attributable to Strong European Natural Gas Prices, Driving an Increased NPV10 of US$2.04 Billion

CanCambria Energy Corp. (TSXV: CCEC) reported an updated independent contingent resource evaluation for its 100% owned Kiskunhalas deep gas project in southern Hungary. Prepared by CHPE (effective June 30, 2026), it assumes $12.00/MMBtu TTF1 gas. Risked 2C Development Pending NPV10 rose 16% to US$2.04B from US$1.762B; 2C volumes are 571.9 Bcf and 59.6 MMbbl. First gas is targeted for mid-2027.